Arteriocyte Recieves FDA Approval to Initiate Cellular Therapy Trial for Treatment of Thermal Burn Wounds in Wounded Warriors
January 31, 2013 - (PRNewswire) - "Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration to initiate a Phase I clinical trial using its Magellan® System technology in the treatment of thermal burn wounds." Read Full Press Release
